Clinical trials · Chicago, IL
Systemic Sclerosis clinical trials in Chicago
We’re tracking 13 recruiting systemic sclerosis studies with a site in or near Chicago — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Chicago, IllinoisAges 18 years+ - NCT06470048RecruitingPhase 2
Testing Ianalumab for Diffuse Cutaneous Systemic Sclerosis
This trial tests a new drug called ianalumab for people with diffuse cutaneous systemic sclerosis (a type of scleroderma affecting the skin and internal organs). It aims to see if the drug can help control the disease activity and reduce skin thickening.
Chicago, IllinoisAges 18–70 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Chicago, IllinoisAges 18–74 - NCT06655896RecruitingPhase 2
Rapcabtagene Autoleucel for severe diffuse scleroderma
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Chicago, IllinoisAges 18–70 - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
Chicago, IllinoisAges 18–70 - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Chicago, IllinoisAges 18 years+ - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Chicago, IllinoisAges 18–75 - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Chicago, IllinoisAges 18 years+ - NCT06328777RecruitingPhase 1/Phase 2
CABA-201 CAR T Cells For Systemic Sclerosis
This trial tests a new treatment called CABA-201, a type of CAR T cell therapy that targets a protein called CD19 on immune cells. It aims to calm the overactive immune system in people with Systemic Sclerosis and may help stop or slow damage to skin, lungs, and other organs.
Chicago, IllinoisAges 18–75 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Chicago, IllinoisAges 18 years+ - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Chicago, IllinoisAges 18–75 - NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Chicago, IllinoisAges 18 years+ - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Willowbrook, IllinoisAges 18 years+
Hear when a new Systemic Sclerosis trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Systemic Sclerosis trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting systemic sclerosis studies listed above.
- University of Chicago · 5 studies
- Northwestern University · 4 studies
- Artiva Investigational Site Willowbrook
- aTyr Investigative Site
- GSK Investigational Site
- Nkarta Investigational Site
- Northwestern Memorial Hospital
- Research Site
What taking part in a systemic sclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting systemic sclerosis studies in Illinois.
Common questions
- Are there systemic sclerosis clinical trials near Chicago?
- Yes. We're currently tracking 13 recruiting systemic sclerosis studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a systemic sclerosis study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New systemic sclerosis studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.